📊 PBYI Key Takeaways
Is Puma Biotechnology, Inc.. (PBYI) a Good Investment?
PBYI is currently unprofitable with negative operating income (-$3.8M) and flat revenue (-0.9% YoY), presenting material fundamental challenges for a pharmaceutical company that typically requires growth to sustain operations. While the company maintains strong liquidity (2.38x current ratio) and positive free cash flow ($15.4M), these cannot offset the lack of revenue growth and persistent operating losses. Without evidence of a turnaround in profitability or revenue acceleration, the business model appears pressured despite adequate balance sheet strength.
Puma Biotechnology, Inc.. Key Strengths (PBYI)
- Strong positive free cash flow of $15.4M with 34.4% FCF margin, providing operational cash generation despite net losses
- Excellent liquidity position with current ratio of 2.38x and $36.2M in cash equivalents
- Conservative financial structure with very low leverage (0.09x Debt/Equity) and manageable $11.3M long-term debt
PBYI Stock Risks: Puma Biotechnology, Inc.. Investment Risks
- Currently unprofitable with negative operating margin (-8.5%) and negative net income (-$3.8M); negative interest coverage (-1.1x) indicates inability to cover interest from operations
- Revenue stagnation at -0.9% YoY decline with no visible growth momentum, highly concerning for pharmaceutical sector requiring expansion to offset R&D costs
- Negative returns on equity (-2.9%) and assets (-1.9%) indicate capital destruction; unclear path to profitability with current business trajectory
Key Metrics to Watch
- Quarterly revenue trend and growth rate inflection
- Operating margin improvement timeline and path to positive EBITDA
- Free cash flow sustainability and monthly cash burn rate to estimate runway
- Product pipeline advancement, clinical trial results, and regulatory approvals
Puma Biotechnology, Inc.. (PBYI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 34.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.38x current ratio provides a solid financial cushion.
PBYI Profit Margin, ROE & Profitability Analysis
PBYI vs Healthcare Sector: How Puma Biotechnology, Inc.. Compares
How Puma Biotechnology, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Puma Biotechnology, Inc.. Stock Overvalued? PBYI Valuation Analysis 2026
Based on fundamental analysis, Puma Biotechnology, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Puma Biotechnology, Inc.. Balance Sheet: PBYI Debt, Cash & Liquidity
PBYI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Puma Biotechnology, Inc..'s revenue has declined by 13% over the 5-year period, indicating business contraction. The most recent EPS of $0.45 reflects profitable operations.
PBYI Revenue Growth, EPS Growth & YoY Performance
PBYI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $44.8M | $3.0M | $0.06 |
| Q3 2025 | $54.5M | $8.8M | $0.17 |
| Q2 2025 | $47.1M | -$4.5M | $-0.09 |
| Q1 2025 | $43.8M | $3.0M | $0.06 |
| Q3 2024 | $56.1M | $5.8M | $0.12 |
| Q2 2024 | $47.1M | $2.1M | $0.05 |
| Q1 2024 | $43.8M | $1.4M | $0.03 |
| Q3 2023 | $56.1M | -$360.0K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Puma Biotechnology, Inc.. Dividends, Buybacks & Capital Allocation
PBYI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Puma Biotechnology, Inc.. (CIK: 0001401667)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PBYI
What is the AI rating for PBYI?
Puma Biotechnology, Inc.. (PBYI) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PBYI's key strengths?
Claude: Strong positive free cash flow of $15.4M with 34.4% FCF margin, providing operational cash generation despite net losses. Excellent liquidity position with current ratio of 2.38x and $36.2M in cash equivalents.
What are the risks of investing in PBYI?
Claude: Currently unprofitable with negative operating margin (-8.5%) and negative net income (-$3.8M); negative interest coverage (-1.1x) indicates inability to cover interest from operations. Revenue stagnation at -0.9% YoY decline with no visible growth momentum, highly concerning for pharmaceutical sector requiring expansion to offset R&D costs.
What is PBYI's revenue and growth?
Puma Biotechnology, Inc.. reported revenue of $44.8M.
Does PBYI pay dividends?
Puma Biotechnology, Inc.. does not currently pay dividends.
Where can I find PBYI SEC filings?
Official SEC filings for Puma Biotechnology, Inc.. (CIK: 0001401667) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PBYI's EPS?
Puma Biotechnology, Inc.. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PBYI's fundamental grade?
Based on our AI fundamental analysis in June 2026, Puma Biotechnology, Inc.. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PBYI stock overvalued or undervalued?
Valuation metrics for PBYI: ROE of -2.9% (sector avg: 15%), net margin of -8.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PBYI's AI grade for 2026?
Our dual AI analysis gives Puma Biotechnology, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PBYI's free cash flow?
Puma Biotechnology, Inc..'s operating cash flow is $15.4M, with capital expenditures of $0.0. FCF margin is 34.4%.
How does PBYI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.4% (avg: 12%), ROE -2.9% (avg: 15%), current ratio 2.38 (avg: 2).